Advertisement

L’Endocrinologo

, Volume 4, Issue 2, pp 90–92 | Cite as

Doping con eritropoietina

  • Andrea Buonamano
  • Paola Romagnani
Article
  • 15 Downloads

Riassunto

L’eritropoietina è un ormone glicoproteico d’origine renale che regola la produzione di globuli rossi. Le eritropoietine usate nella terapia dell’anemia da insufficienza renale e nei pazienti neoplastici sono preparate con tecniche ricombinanti mediante transfezione del gene umano in cellule di mammifero. Di conseguenza le eritropoietine ricombinanti possiedono un maggior contenuto zuccherino. Quest a caratteristica le rende riconoscibili nelle urine mediante tecniche immunoelettroforetiche. Ancor meglio riconoscibile è la darbopoietina perché possiede un maggior numero di molecole d’acido sialico. Le suddette tecniche sono quindi impiegate per rivelare l’uso di eritropoietine nel doping degli atleti.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Bibliografia

  1. 1.
    Krantz SB. Erythropoietin. Blood 77: 419, 1991.PubMedGoogle Scholar
  2. 2.
    D’Andrea AD, Zon LI. Erythropoietin receptor. Subunit structure and activation. J Clin Invest 86: 681, 1990.PubMedCentralPubMedCrossRefGoogle Scholar
  3. 3.
    Youssoufian H, Longmore G, Neumann D, Yoshimura A, Lodish HF. Structure, function, and activation of the erythropoietin receptor. Blood 81: 2223, 1993.PubMedGoogle Scholar
  4. 4.
    Vanrenterghem Y, Barany P, Mann JF, Kerr PG, Wilson J, Baker NF, Gray SJ; European/Australian NESP 970200 Study Group. Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients. Kidney Int 62: 2167, 2002.PubMedCrossRefGoogle Scholar
  5. 5.
    Rizzo JD, Lichtin AE, Woolf SH, Seidenfeld J, Bennett CL, Cella D, Djulbegovic B, Goode MJ, Jakubowski AA, Lee SJ, Miller CB, Rarick MU, Regan DH, Browman GP, Gordon MS. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 20: 4083, 2002.PubMedCrossRefGoogle Scholar
  6. 6.
    Cazzola M. A global strategy for prevention and detection of blood doping with erythropoietin and related drugs. Haematologica 85: 561, 2000.PubMedGoogle Scholar
  7. 7.
    Cazzola M. Further concerns about the medical risks of blood doping. Haematologica 87: 232, 2002.PubMedGoogle Scholar
  8. 8.
    Stanley SM, Poljak A. Matrix-assisted laser-desorption time-of flight ionisation and high-performance liquid chromatography-electrospray ionisation mass spectral analyses of two glycosylated recombinant epoetins. J Chromatogr B Analyt Technol Biomed Life Sci 785: 205, 2003.PubMedCrossRefGoogle Scholar
  9. 9.
    Caldini A, Moneti G, Fanelli A, Bruschettini A, Mercurio S, Pieraccini G, Cini E, Ognibene A, Luceri F, Messeri G. Epoetin alpha, epoetin beta and darbopoetin alfa: 2-DE isoform characterisation and MS analysis. Proteomics in Press.Google Scholar
  10. 10.
    Lasne F, Martin L, Crepin N, de Ceaurriz J. Detection of isoelectric profiles of erythropoietin in urine: differentiation of natural and administered recombinant hormones. Anal Biochem 311: 119, 2002.PubMedCrossRefGoogle Scholar
  11. 11.
    Lasne F, De Ceaurriz J. Recombinant erythropoietin in urine. Nature 405: 635, 2000.PubMedCrossRefGoogle Scholar
  12. 12.
    Catlin DH, Breidbach A, Elliott S, Glaspy J. Comparison of the isoelectric focusing patterns of darbepoetin alfa, recombinant human erythropoietin, and endogenous erythropoietin from human urine. Clin Chem 48: 2057, 2002.PubMedGoogle Scholar

Copyright information

© Springer International Publishing AG 2003

Authors and Affiliations

  1. 1.Unità di Endocrinologia, Dipartimento di Fisiopatologia ClinicaUniversità di FirenzeFirenzeItalia

Personalised recommendations